부산대학교 도서관

Stem Cell Week. February 23, 2015, p50.

Woan, KV; Kim, H; Bjordahl, R; Davis, ZB; Gaidarova, S; Goulding, J; Hancock, B; Mahmood, S; Abujarour, R; Wang, H

CELL STEM CELL. 28(12):2062

Hosking MP; Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: martin.hosking@fatetherapeutics.com.; Shirinbak S; Fate Therapeutics, Inc., San Diego, CA, USA.; Omilusik K; Fate Therapeutics, Inc., San Diego, CA, USA.; Chandra S; Fate Therapeutics, Inc., San Diego, CA, USA.; Kaneko MK; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.; Gentile A; Fate Therapeutics, Inc., San Diego, CA, USA.; Yamamoto S; Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Shrestha B; Fate Therapeutics, Inc., San Diego, CA, USA.; Grant J; Fate Therapeutics, Inc., San Diego, CA, USA.; Boyett M; Fate Therapeutics, Inc., San Diego, CA, USA.; Cardenas D; Fate Therapeutics, Inc., San Diego, CA, USA.; Keegan H; Fate Therapeutics, Inc., San Diego, CA, USA.; Ibitokou S; Fate Therapeutics, Inc., San Diego, CA, USA.; Pavon C; Fate Therapeutics, Inc., San Diego, CA, USA.; Mizoguchi T; Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Ihara T; Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Nakayama D; Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Abujarour R; Fate Therapeutics, Inc., San Diego, CA, USA.; Lee TT; Fate Therapeutics, Inc., San Diego, CA, USA.; Clarke R; Fate Therapeutics, Inc., San Diego, CA, USA.; Goodridge J; Fate Therapeutics, Inc., San Diego, CA, USA.; Peralta E; Fate Therapeutics, Inc., San Diego, CA, USA.; Maeda T; Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Takagi J; Institute for Protein Research, Osaka University, 3-2, Yamadaoka, Suita 565-0871, Osaka, Japan.; Arimori T; Institute for Protein Research, Osaka University, 3-2, Yamadaoka, Suita 565-0871, Osaka, Japan.; Kato Y; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.; Valamehr B; Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: bob.valamehr@fatetherapeutics.com.

Publisher: Cell Press Country of Publication: United States NLM ID: 101311472 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1875-9777 (Electronic) Linking ISSN: 18759777 NLM ISO Abbreviation: Cell Stem Cell Subsets: MEDLINE

Lu D; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Chu HY; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Park S; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Landon M; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Tsuda M; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Avramis E; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Dege C; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Dailey T; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Pan Y; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Hanok SK; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Denholtz M; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Abujarour R; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Lee T; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Goulding J; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Hosking M; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Goodridge J; Fate Therapeutics, Inc., San Diego, CA 92131, USA.; Peralta E; Fate Therapeutics, Inc., San Diego, CA 92131, USA. Electronic address: eigen.peralta@fatetherapeutics.com.; Valamehr B; Fate Therapeutics, Inc., San Diego, CA 92131, USA. Electronic address: bob.valamehr@fatetherapeutics.com.

Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

Greene, T. ; Peng, S. ; Bickers, C. ; Lunning, M. ; Lulla, P. ; Bachanova, V. ; Williams, A. ; Morales-Mantilla, D. ; Mbofung, R. ; Aguilar, A. ; Brookhouser, N. ; Reeder, S. ; Zhao, W. ; Patel, D. ; Abujarour, R. ; Lee, T. ; Clarke, R. ; Rezner, B. ; Goodridge, J. ; Elstrom, R. ; Zack, D. ; Sandhu, V. ; Valamehr, B. ; Wong, L.

In Annals of the Rheumatic Diseases June 2025 84 Supplement 1:1423-1424

Genomics & Genetics Weekly. May 16, 2014, p133.

Abujarour R; Fate Therapeutics, San Diego, CA 92121, USA.; Dinella J; Fate Therapeutics, San Diego, CA 92121, USA.; Pribadi M; Fate Therapeutics, San Diego, CA 92121, USA.; Fong LK; Fate Therapeutics, San Diego, CA 92121, USA.; Denholtz M; Fate Therapeutics, San Diego, CA 92121, USA.; Gutierrez A; Fate Therapeutics, San Diego, CA 92121, USA.; Haynes M; Fate Therapeutics, San Diego, CA 92121, USA.; Mahmood E; Fate Therapeutics, San Diego, CA 92121, USA.; Lee TT; Fate Therapeutics, San Diego, CA 92121, USA.; Ding S; School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.; Valamehr B; Fate Therapeutics, San Diego, CA 92121, USA.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 101665030 Publication Model: eCollection Cited Medium: Print ISSN: 2056-5623 (Print) Linking ISSN: 20565623 NLM ISO Abbreviation: Future Sci OA Subsets: PubMed not MEDLINE

Goulding, J. ; Reiser, J. ; O'Connor, A. ; Morales-Mantilla, D. ; Mbofung, R. ; Williams, A. ; Gutierrez, A. ; Jelcic, M. ; Pan, Y. ; Groff, B. ; Macia, A. ; Brookhouser, N. ; Greene, T. ; Raman, S. ; Janani, R. ; Hancock, B. ; Denholtz, M. ; Rezner, B. ; Abujarour, R. ; Wong, L. ; Sandhu, V. ; Lee, T. ; Valamehr, B. ; Goodridge, J.

In Annals of the Rheumatic Diseases June 2025 84 Supplement 1:368-368

Science Letter. April 12, 2013, p931.

Greene, T.; Peng, S.; Bickers, C.; Lunning, M.; Lulla, P.; Bachanova, V.; Williams, A.; Morales-Mantilla, D.; Mbofung, R.; Aguilar, A.; Brookhouser, N.; Reeder, S.; Zhao, W.; Patel, D.; Abujarour, R.; Clarke, R.; Lee, T.; Rezner, B.; Goodridge, J.; Elstrom, R.; Zack, D.; Sandhu, V.; Wong, L.; Valamehr, B.

ANNALS OF THE RHEUMATIC DISEASES; JUN 2025, 84 2p. Supplement: 1

van der Stegen SJC; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Lindenbergh PL; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands.; Petrovic RM; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Xie H; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Diop MP; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Alexeeva V; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Shi Y; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Mansilla-Soto J; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Hamieh M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Eyquem J; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Gladstone-UCSF Institute of Genomic Immunology, Gladstone Institutes, San Francisco, CA, USA.; Cabriolu A; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Wang X; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Abujarour R; Fate Therapeutics Inc, San Diego, CA, USA.; Lee T; Fate Therapeutics Inc, San Diego, CA, USA.; Clarke R; Fate Therapeutics Inc, San Diego, CA, USA.; Valamehr B; Fate Therapeutics Inc, San Diego, CA, USA.; Themeli M; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands.; Riviere I; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Sadelain M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. m-sadelain@ski.mskcc.org.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. m-sadelain@ski.mskcc.org.

Publisher: Springer Nature Country of Publication: England NLM ID: 101696896 Publication Model: Print Cited Medium: Internet ISSN: 2157-846X (Electronic) Linking ISSN: 2157846X NLM ISO Abbreviation: Nat Biomed Eng Subsets: MEDLINE; PubMed not MEDLINE

Chandra, S; Reiser, J; Groff, B; Dege, C; Hancock, B; O'Connor, A; Gutierrez, A; Gentile, A; Lee, T; Abujarour, R

BLOOD. 146:4121-4121

Goulding, J.; Reiser, J.; O'Connor, A.; Morales-Mantilla, D.; Mbofung, R.; Williams, A.; Gutierrez, A.; Jelcic, M.; Pan, Y.; Groff, B.; Macia, A.; Brookhouser, N.; Greene, T.; Raman, S.; Janani, R.; Hancock, B.; Denholtz, M.; Rezner, B.; Abujarour, R.; Wong, L.; Sandhu, V.; Lee, T.; Valamehr, B.; Goodridge, J.

ANNALS OF THE RHEUMATIC DISEASES; JUN 2025, 84 p367-p368, 2p. Supplement: 1

Cichocki F; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA.; Bjordahl R; Fate Therapeutics, San Diego, CA, 92121, USA.; Goodridge JP; Fate Therapeutics, San Diego, CA, 92121, USA.; Mahmood S; Fate Therapeutics, San Diego, CA, 92121, USA.; Gaidarova S; Fate Therapeutics, San Diego, CA, 92121, USA.; Abujarour R; Fate Therapeutics, San Diego, CA, 92121, USA.; Davis ZB; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA.; Merino A; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA.; Tuininga K; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA.; Wang H; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA.; Kumar A; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA.; Groff B; Fate Therapeutics, San Diego, CA, 92121, USA.; Witty A; Fate Therapeutics, San Diego, CA, 92121, USA.; Bonello G; Fate Therapeutics, San Diego, CA, 92121, USA.; Huffman J; Fate Therapeutics, San Diego, CA, 92121, USA.; Dailey T; Fate Therapeutics, San Diego, CA, 92121, USA.; Lee TT; Fate Therapeutics, San Diego, CA, 92121, USA.; Malmberg KJ; Oslo University Hospital, Oslo, Norway.; Walcheck B; University of Minnesota, Department of Veterinary and Biomedical Sciences, St. Paul, MN, 55108, USA.; Höpken U; Max-Delbrück-Center for Molecular Medicine, MDC, Berlin, Germany.; Rehm A; Max-Delbrück-Center for Molecular Medicine, MDC, Berlin, Germany.; Valamehr B; Fate Therapeutics, San Diego, CA, 92121, USA. bob.valamehr@fatetherapeutics.com.; Miller JS; University of Minnesota, Department of Medicine, Minneapolis, MN, 55455, USA. mille011@umn.edu.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Hammer Q; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Electronic address: quirin.hammer@ki.se.; Perica K; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Mbofung RM; Fate Therapeutics, Inc., San Diego, CA, USA.; van Ooijen H; Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Solna, Sweden.; Martin KE; Precision Immunotherapy Alliance, Institute for Cancer Research, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Momayyezi P; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.; Varady E; Fate Therapeutics, Inc., San Diego, CA, USA.; Pan Y; Fate Therapeutics, Inc., San Diego, CA, USA.; Jelcic M; Fate Therapeutics, Inc., San Diego, CA, USA.; Groff B; Fate Therapeutics, Inc., San Diego, CA, USA.; Abujarour R; Fate Therapeutics, Inc., San Diego, CA, USA.; Krokeide SZ; Precision Immunotherapy Alliance, Institute for Cancer Research, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Lee T; Fate Therapeutics, Inc., San Diego, CA, USA.; Williams A; Fate Therapeutics, Inc., San Diego, CA, USA.; Goodridge JP; Fate Therapeutics, Inc., San Diego, CA, USA.; Valamehr B; Fate Therapeutics, Inc., San Diego, CA, USA.; Önfelt B; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Solna, Sweden.; Sadelain M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Malmberg KJ; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Precision Immunotherapy Alliance, Institute for Cancer Research, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. Electronic address: k.j.malmberg@medisin.uio.no.

Publisher: Cell Press Country of Publication: United States NLM ID: 101311472 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1875-9777 (Electronic) Linking ISSN: 18759777 NLM ISO Abbreviation: Cell Stem Cell Subsets: MEDLINE

Hammer Q; Perica K; van Ooijen H; Mbofung R; Momayyezi P; Varady E; Martin KE; Pan Y; Jelcic M; Groff B; Abujarour R; Krokeide S; Lee T; Williams A; Goodridge JP; Valamehr B; Önfelt B; Sadelain M; Malmberg KJ

Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Cichocki F; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.; Bjordahl R; Fate Therapeutics, San Diego, CA 92121, USA.; Gaidarova S; Fate Therapeutics, San Diego, CA 92121, USA.; Mahmood S; Fate Therapeutics, San Diego, CA 92121, USA.; Abujarour R; Fate Therapeutics, San Diego, CA 92121, USA.; Wang H; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.; Tuininga K; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.; Felices M; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.; Davis ZB; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.; Bendzick L; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.; Clarke R; Fate Therapeutics, San Diego, CA 92121, USA.; Stokely L; Fate Therapeutics, San Diego, CA 92121, USA.; Rogers P; Fate Therapeutics, San Diego, CA 92121, USA.; Ge M; Fate Therapeutics, San Diego, CA 92121, USA.; Robinson M; Fate Therapeutics, San Diego, CA 92121, USA.; Rezner B; Fate Therapeutics, San Diego, CA 92121, USA.; Robbins DL; Fate Therapeutics, San Diego, CA 92121, USA.; Lee TT; Fate Therapeutics, San Diego, CA 92121, USA.; Kaufman DS; Department of Medicine, Division of Regenerative Medicine, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA 92093, USA.; Blazar BR; Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.; Valamehr B; Fate Therapeutics, San Diego, CA 92121, USA. mille011@umn.edu bob.valamehr@fatetherapeutics.com.; Miller JS; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. mille011@umn.edu bob.valamehr@fatetherapeutics.com.

Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

Cichocki F; Department of Medicine, University of Minnesota, Minneapolis, MN.; Goodridge JP; Fate Therapeutics, San Diego, CA.; Bjordahl R; Fate Therapeutics, San Diego, CA.; Mahmood S; Fate Therapeutics, San Diego, CA.; Davis ZB; Department of Medicine, University of Minnesota, Minneapolis, MN.; Gaidarova S; Fate Therapeutics, San Diego, CA.; Abujarour R; Fate Therapeutics, San Diego, CA.; Groff B; Fate Therapeutics, San Diego, CA.; Witty A; Fate Therapeutics, San Diego, CA.; Wang H; Department of Medicine, University of Minnesota, Minneapolis, MN.; Tuininga K; Department of Medicine, University of Minnesota, Minneapolis, MN.; Kodal B; Department of Medicine, University of Minnesota, Minneapolis, MN.; Felices M; Department of Medicine, University of Minnesota, Minneapolis, MN.; Bonello G; Fate Therapeutics, San Diego, CA.; Huffman J; Fate Therapeutics, San Diego, CA.; Dailey T; Fate Therapeutics, San Diego, CA.; Lee TT; Fate Therapeutics, San Diego, CA.; Walcheck B; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN.; Valamehr B; Fate Therapeutics, San Diego, CA.; Miller JS; Department of Medicine, University of Minnesota, Minneapolis, MN.

Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

van der Stegen SJC; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Lindenbergh PL; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands.; Petrovic RM; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Xie H; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Diop MP; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Alexeeva V; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Shi Y; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Mansilla-Soto J; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Hamieh M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Eyquem J; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Gladstone-UCSF Institute of Genomic Immunology, Gladstone Institutes, San Francisco, CA, USA.; Cabriolu A; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Wang X; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Abujarour R; Fate Therapeutics Inc, San Diego, CA, USA.; Lee T; Fate Therapeutics Inc, San Diego, CA, USA.; Clarke R; Fate Therapeutics Inc, San Diego, CA, USA.; Valamehr B; Fate Therapeutics Inc, San Diego, CA, USA.; Themeli M; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands.; Riviere I; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Sadelain M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. m-sadelain@ski.mskcc.org.; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. m-sadelain@ski.mskcc.org.

Publisher: Springer Nature Country of Publication: England NLM ID: 101696896 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2157-846X (Electronic) Linking ISSN: 2157846X NLM ISO Abbreviation: Nat Biomed Eng Subsets: MEDLINE

Hammer, Q; Perica, K; Mbofung, RM; van, Ooijen H; Varady, E; Jelcic, M; Pan, Y; Momayyezi, P; Groff, B; Abujarour, R

BLOOD. 140:1165-1166